GlassScriptPhysician profile
Jeffrey L Martz
NPI 1376013771
$4,176.85
in general payments reported to CMS, 2019-2025
33 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,104 · 2023: $1,245 · 2024: $515 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.40 | 2022-2025 | |
| Novo Nordisk INC | $458.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.40 | 2022-2025 | Jardiance |
| Pfizer INC. | $292.57 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $291.35 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $282.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $238.15 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $220.91 | 2023-2025 | Freestyle Libre 2, Proclaim, Optis |
| Bayer Healthcare Pharmaceuticals INC. | $205.55 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $204.27 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.02 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $131.19 | 2022-2023 | Injectafer |
| Amgen INC. | $110.77 | 2022-2025 | Repatha, Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $109.67 | 2022 | |
| Exact Sciences Corporation | $95.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $94.26 | 2023-2025 | Veozah |
| Dexcom, INC. | $65.17 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2023 | |
| Amarin Pharma, INC. | $45.17 | 2022 | |
| Medtronic, INC. | $39.23 | 2022-2023 | Venaseal |
| Kaleo, INC. | $38.48 | 2022 | |
| Bausch Health US, LLC | $34.68 | 2022-2023 | Aplenzin |
| Sanofi Pasteur INC. | $31.46 | 2023 | |
| Azurity Pharmaceuticals, INC. | $30.32 | 2025 | Horizant |
| Vertex Pharmaceuticals Incorporated | $26.84 | 2025 | |
| Edwards Lifesciences Corporation | $23.28 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.27 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $19.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.93 | 2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $18.80 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $14.64 | 2023 | Inspire |
| Supernus Pharmaceuticals, INC. | $14.46 | 2025 | Qelbree |
| Antares Pharma, INC. | $13.46 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Martz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.